Two studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a ...

Imunon Inc. (IMNN) reported its third-quarter 2025 financial results, highlighting a significant reduction in net loss and operating expenses. Despite these positive financial metrics, the company’s ...

R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for ...

Imunon Inc (NASDAQ:IMNN) is making significant progress with its IL-12 immunotherapy, Immunon 001, particularly in the Ovation 3 pivotal phase 3 trial for advanced ovarian cancer. The Ovation 2 study ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Earnings call Imunon reported a Q3 2025 net loss of $3.4M, down from $4.8M YoY, driven by a 31% reduction in operating expenses. The company beat internal enrollment targets for its phase III OVATION ...

Dr. Stacy Lindborg, Imunon's President and Chief Executive Officer. Stacy. Stacy Lindborg: Thank an you, Peter, and good morning, everyone. Joining me on the call this morning is Dr. Douglas Faller, ...